Navigation Links
Pfenex Inc. awarded a subcontract by Leidos to develop a scalable cGMP production process for a second key malaria antigen
Date:10/29/2013

SAN DIEGO, Oct. 29, 2013 /PRNewswire/ -- Pfenex Inc. today announced that Leidos Holdings, Inc. (NYSE: LDOS) (formerly SAIC) has awarded Pfenex a subcontract to develop a robust, scalable, cGMP-ready production process for large-scale production of the blood-stage malaria antigen Plasmodium falciparum reticulocyte-binding homolog 5 (Rh5). This contract is a result of successful pre-clinical studies performed by Leidos collaborators to evaluate the Rh5 antigen that was produced using the Pfēnex Expression TechnologyTM platform. The subcontract is funded with federal funds from Leidos' prime Malaria Vaccine Production and Support Services (MVPSS) contract (N01.AI.05421) from the National Institute of Allergy and Infectious Diseases (NIAID).

This is the second subcontract awarded to Pfenex for the development of critical, hard-to-express malaria antigens.  Leidos had previously awarded Pfenex a subcontract to develop a scalable, cGMP-ready production process for large-scale production of full length Circumsporozoite protein (CSP) from P. falciparum.

"We are pleased to be awarded this contract as we expand our effort to find an effective therapy for malaria," stated Bertrand C. Liang, Pfenex's Chief Executive Officer. "Pfēnex Expression TechnologyTM has once again demonstrated its ability to efficiently produce a high–value, complex protein enabling the potential of a multivalent malaria vaccine."

Pfenex will immediately commence process development activities while continuing to provide materials to Leidos and NIAID for ongoing preclinical studies. 

"Working with Pfenex and NIAID on this program is an important step in the development of an effective malaria vaccine," said James Pannucci, Ph.D., vice president of the Leidos Health Life Sciences team.  "We hope our work will lead to new discoveries and have a profound effect on the world's health." The Leidos Life Science team operates a virtual drug development enterprise that bridges the gap between federal agencies and commercial clients, along with a modest portfolio of vaccine and therapeutic candidates.

About Pfenex Inc.  
Pfenex Inc. is a biotechnology company developing biosimilars and innovative vaccines to address unmet and growing global healthcare needs.  Utilizing the company's core technology, Pfēnex Expression Technology™ for recombinant protein expression, Pfenex is able to rapidly develop and produce high quality biopharmaceuticals. In addition, Pfenex also produces and markets research proteins and reagent proteins for the research and drug development community through its Reagent Proteins division.  For more information please visit www.pfenex.com 


'/>"/>
SOURCE Pfenex Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Pfenex Inc. and Agila Biotech Private Limited Announce Joint Venture to Develop Biosimilar Products for the Global Market
2. Biomedical Advanced Research and Development Authority (BARDA) Exercises Option with Pfenex Inc. To Extend Contract for the Development of a Recombinant Protective Antigen (rPA) Based Anthrax Vaccine
3. AMRI Awarded Development and Manufacture Contract from the UK Government
4. Numotion Awarded Best Complex Rehab Provider
5. Isis Pharmaceuticals Stanley Crooke Awarded Corporate Forums Director of the Year
6. Access Pharmaceuticals Awarded Second European Patent for MuGard
7. Jeannette R. Jakus, MD, MBA, Awarded American Academy of Dermatology Translational Biotechnology Fellowship
8. Oligomerix Awarded Phase IIB Grant From the NIH to Discover Drugs that Inhibit Alzheimers Disease Progression
9. NovelMed Awarded NIH Fast Track SBIR Grant for $1.43 Million to Advance Development of its Anti-Complement Antibody for Orphan Disease
10. Carolina Piedmont Capital Awarded VOSB Certification
11. B. Braun Awarded Premier Healthcare Alliance Contract for Dual-Source IV
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/17/2017)... , August 17, 2017 DarioHealth ... Company with mobile health and big data solutions, ... agreements with domestic and non-U.S. investors for the ... and shares of the Company,s newly designated Series ... offerings. The Company expects to conduct a closing ...
(Date:8/15/2017)... HOUSTON , Aug. 15, 2017   Mostyn Law ... in Houston, Texas . The Mostyn Law ... the past 2 years. That is why Mostyn Law ... Texas to show its appreciation. Blood supplies ... to fall 5% short of hospital needs in August. That is ...
(Date:8/15/2017)... Aug. 15, 2017  Axium Pharmaceuticals Inc., the creator of the drug ... in the beginning stages of an IPO. The ... with the average cost of a prescription epilepsy drug being $450.00-$1200.00 for ... AXIUM PHARMACEUTICALS, INC ... Another staggering figure is the fact that Americans spent ...
Breaking Medicine Technology:
(Date:8/18/2017)... ... August 18, 2017 , ... Radabaugh & Associates, a ... communities in North-Central West Virginia, is embarking on a cooperative charity effort with ... area. , The Chestnut Mountain Ranch (CMR) is a Christ-centered boarding school for ...
(Date:8/18/2017)... ... 2017 , ... The Brian Gifford Agency, an Indiana-based firm providing asset protection ... Campagna Academy in a charity drive to provide for at-risk children and teens in ... Academy is a nonprofit organization that has offered critical programs to at-risk and foster ...
(Date:8/18/2017)... ... 2017 , ... “Emotions are sacred, valid, honored, encouraged. This is the memo ... Generation Mindful. To help change the mindset of parents and educators from punitive to ... the Time-In Toolkit, which launched on Kickstarter 3 weeks ago and fully funded in ...
(Date:8/18/2017)... ... 18, 2017 , ... Alcovit, a lime-flavored beverage that rids the body of ... its product now available through Jet.com. , After 25 years of development, the ... is designed to quickly detox the body thereby avoiding alcohol-induced hangovers. Whether you’re having ...
(Date:8/18/2017)... ... ... “Our Mountains to Climb: A Journey of Love and Faith Through Trials”: ... faith they shared to overcome struggles in life. “Our Mountains to Climb: A Journey ... Corcoran, a retired teacher and happily married since 1999; the author’s personal experiences drive ...
Breaking Medicine News(10 mins):